Loading stock data…
Century Therapeutics (IPSC)
$2.11-0.06 (-2.76%)
Market ClosedLast close Jul 24
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Century Therapeutics, Inc. in the Healthcare sector is trading at $2.11 with a market capitalization of $401M. Wall Street consensus targets $4.75 (4 analysts), implying a +125.1% move over the next 12 months. The stock is currently 31% below its 52-week high of $3.04, remaining 22.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +125.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $109.16M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.68M↓ | -$20.65M↑ | -$29.36M↑ | -$34.66M↓ | $74.18M |
| Net Income | -$21.64M↓ | -$19.17M↑ | -$34.42M↓ | -$32.54M↓ | $76.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derive...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$401.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.71%
Volume
Today's trading volume
657,603
Recent News
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses. Both presentations will highlight CNTY-813, Century’s iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients […]
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
Century Therapeutics, Inc. (NASDAQ:IPSC), featuring a year-to-date gain of 114.11% and upside potential of 134.70%, secures a spot on our list of hot biotech stocks under $5 to buy. New preclinical data presented at a major diabetes conference made the case that Century Therapeutics, Inc. (NASDAQ:IPSC)’s lead iPSC-derived therapy could one day offer a functional […]
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright lifted the price target on Century Therapeutics, Inc. (NASDAQ:IPSC) to $5 from $2 on April 21, maintaining a Buy rating on the shares. The firm told investors in a research note that Vertex has shown stem-cell islets […]
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission
Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company’s plan to submit an IND for CNTY-813 this year and deliver initial data by […]